Spondyloarthritis & psoriatic arthritis
Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register
An erratum to this article was published (Arthritis Res Ther, 21 May 2026 ↗)
Study context
- Population
- Bionaïve patients with psoriatic arthritis (PsA) starting their first b/tsDMARD, German RABBIT-SpA register
- Participants
- 457 vs 343
- Exposure
- Females vs males with PsA starting first-line b/tsDMARD
- Femalesn = 457
- Malesn = 343reference
- Outcome
- Therapy persistence on first-line b/tsDMARD
Methodological detailsregister analysis, real-world, Cox regression adjusted for age, descriptive analyses
- Register analysis
- Real-world
- Cox regression adjusted for age
- Descriptive analyses
Main finding
As reported in the abstract
Remaining on initial b/tsDMARD therapy · 12 months
Observational data: associations, not effects.
Further findings
Treatment persistence, TNFi and IL17i subgroups
- Females had lower treatment persistence rates in subgroups restricted to TNFi and IL17i
Reasons for therapy discontinuation
- Males more frequently discontinued due to lack of efficacy or remission; females more often due to adverse events
Baseline disease characteristics
- Females: more severe joint involvement, higher disease activity, more pain, greater functional limitations; males: more pronounced skin involvement and higher prevalence of nail psoriasis
Safety
- Females experienced a greater number of overall adverse events; males reported serious adverse events at twice the rate
Original publication
Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register. Arthritis Res Ther. Published 2 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →